KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC) Meeting Abstract


Authors: Lee, C. H.; Li, C.; Perini, R. F.; Hoehn, D.; Albiges, L.
Abstract Title: KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
Meeting Title: 2021 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 39
Issue: 15 Suppl.
Meeting Dates: 2021 Jun 4-8
Meeting Location: Virtual
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2021-05-20
Language: English
ACCESSION: WOS:000708120306288
DOI: 10.1200/JCO.2021.39.15_suppl.TPS4595
PROVIDER: wos
Notes: Meeting Abstract: TPS4595 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Chung-Han   Lee
    157 Lee